ORAMED PHARMACEUTICALS INC. - FORM 10-K - EX-32.2 - CERTIFICATION - November 25, 2015

Attached files

file filename
EX-10.4 - AMENDMENT, DATED JULY 21, 2015, TO CONSULTING AGREEMENTS BY AND BETWEEN ORAMED LTD. AND KNRY, LTD. - ORAMED PHARMACEUTICALS INC.f10k2015ex10iv_oramed.htm
EX-10.12 - AMENDMENT TO EMPLOYMENT AGREEMENT, DATED AS OF JULY 17, 2013, BY AND BETWEEN ORAMED LTD. AND YIFAT ZOMMER - ORAMED PHARMACEUTICALS INC.f10k2015ex10xii_oramed.htm
EX-10.13 - AMENDMENT TO EMPLOYMENT AGREEMENT, DATED AS OF JULY 21, 2015, BY AND BETWEEN ORAMED LTD. AND YIFAT ZOMMER - ORAMED PHARMACEUTICALS INC.f10k2015ex10xiii_oramed.htm
EX-31.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2015ex31i_oramed.htm
EX-32.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2015ex32i_oramed.htm
EX-10.25 - AMENDMENT TO EMPLOYMENT AGREEMENT, DATED JULY 21, 2015, BETWEEN ORAMED LTD. AND JOSHUA HEXTER - ORAMED PHARMACEUTICALS INC.f10k2015ex10xxv_oramed.htm
EX-10.22 - AGREEMENT AND AMENDMENT NO. 2, DATED APRIL 1, 2015, WITH DR. MICHAEL BERELOWITZ - ORAMED PHARMACEUTICALS INC.f10k2015ex10xxii_oramed.htm
10-K - ANNUAL REPORT - ORAMED PHARMACEUTICALS INC.f10k2015_oramedpharma.htm
EX-31.2 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k201531ii_oramed.htm
EX-23.1 - CONSENT OF KESSELMAN & KESSELMAN, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - ORAMED PHARMACEUTICALS INC.f10k2015ex23i_oramed.htm
EX-10.5 - AMENDMENT, DATED JULY 21, 2015, TO CONSULTING AGREEMENTS BY AND BETWEEN ORAMED LTD. AND KNRY, LTD. - ORAMED PHARMACEUTICALS INC.f10k2015ex10v_oramed.htm

Exhibit 32.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

 

In connection with the annual report of Oramed Pharmaceuticals Inc., or the Company, on Form 10-K for the period ended August 31, 2015, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Yifat Zommer, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:

 

1.   The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and
   
2.   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: November 25, 2015 /s/ Yifat Zommer  
  Yifat Zommer
Chief Financial Officer

 

 

 

Stock widget

Investing forum

ORAMED PHARMACEUTICALS INC. Reports